Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
Jonathan W. Riess(University of California Davis Medical Center), Siraj M. Ali(UPMC Hillman Cancer Center), Lee A. Albacker(Foundation Medicine (United States)), Shakti Ramkissoon(Foundation Medicine (United States)), Claire Edgerly(Foundation Medicine (United States)), Russell W. Madison(Foundation Medicine (United States)), Nir Peled(Shaare Zedek Medical Center), Brian M. Alexander(Brigham and Women's Hospital), Alexa B. Schrock(GlobalFoundries (United States)), Waleed Kian(Soroka Medical Center), Dexter X. Jin(Foundation Medicine (United States)), Ethan S. Sokol(Foundation Medicine (United States)), Samuel J. Klempner(Broad Institute), Garrett M. Frampton(Tech Foundation), Shaila Rahman, Jon Chung(Foundation Medicine (United States)), Jeffrey S. Ross(Unknown), Andreas Heilmann(Foundation Medicine (United States)), Vincent A. Miller(Universidad San Carlos), Jeffrey P. Gregg(University of California Davis Medical Center), Sally E. Trabucco(Foundation Medicine (United States)), Shai Shlomi klaitman(Sheba Medical Center), Laila C. Roisman(Shaare Zedek Medical Center)
Cited by 19
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
|Genome Medicine|2017|3.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k